Gilead Sciences filings document material events, operating results, governance matters and capital-structure disclosures for a Delaware biopharmaceutical company whose common stock trades as GILD on the Nasdaq Global Select Market. Form 8-K reports furnish quarterly and annual financial results, including GAAP and non-GAAP measures and reconciliations, and disclose completed acquisition activity affecting oncology pipeline assets.
Proxy and annual meeting filings record director elections, auditor ratification and shareholder voting outcomes. Other current reports cover executive and governance changes, Regulation FD disclosures, material agreements, and formal exhibits tied to Gilead’s virology and oncology business, including clinical or regulatory disclosure categories when they are part of the company’s public reporting.
Gilead Sciences chairman and CEO Daniel P. O'Day reported an automatic insider transaction involving stock options and common shares. On February 5, 2026, he exercised 115,640 non-qualified stock options at a price of $66.01 per share and received the same number of common shares.
That same day, he sold 115,640 shares of Gilead common stock at $150 per share under a Rule 10b5-1 trading plan adopted on February 28, 2025. After these transactions, he directly owned 613,912 shares of Gilead common stock.
Gilead Sciences officer Johanna Mercier, Chief Commercial & Corporate Affairs Officer, reported performance-based stock awards on common shares. On February 3, 2026, she acquired 44,867 shares at $0 following certification that performance goals were met for awards granted in March 2023 and March 2024.
On the same date, 24,800 shares were withheld at $143.28 per share, likely for tax obligations, leaving her with 123,288 shares of Gilead common stock held directly. Portions of the 2024 award will be issued only after additional service requirements are satisfied.
Gilead Sciences Chief Financial Officer Andrew D. Dickinson reported equity-related transactions in company common stock. On February 3, 2026, he acquired 44,867 shares of common stock at $0 per share, tied to performance share awards granted on March 10, 2023 and March 10, 2024.
These awards vested after the Compensation and Talent Committee certified achievement of performance goals, though shares from the March 10, 2024 grant will only be issued once additional service requirements are met. On the same date, he had a disposition coded "F" of 24,802 shares at $143.28 per share. Following these transactions, Dickinson directly owns 170,568 shares of Gilead common stock.
Gilead Sciences Chairman and CEO Daniel P. O'Day reported equity compensation activity involving the company’s common stock. On February 3, 2026, he acquired 131,675 shares at $0 under performance share awards granted in March 2023 and March 2024 after performance goals were certified.
On the same date, 74,461 shares were disposed of at $143.28, typically reflecting shares withheld to cover taxes on the vesting. After these transactions, O'Day directly owned 613,912 shares of Gilead common stock. Portions of the 2024 performance award will only be issued once additional service-vesting requirements are met.
Daniel O'Day filed to sell 115640 shares of Gilead common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of 17346000.00 and 1240679623 Gilead shares outstanding.
The 115640 shares were acquired on 02/05/2026 via a stock option exercise from the issuer, paid in cash on the same date. Over the prior three months, O'Day sold additional Gilead common shares in four trades totaling 145640 shares for gross proceeds of 187627,? wait.
FMR LLC has disclosed a significant ownership stake in Gilead Sciences Inc. As of 12/31/2025, FMR LLC reported beneficial ownership of 65,539,476.75 shares of Gilead common stock, representing 5.3% of the outstanding class.
FMR LLC has sole voting power over 57,299,411.36 shares and sole dispositive power over 65,539,476.75 shares, with no shared voting or dispositive power. Abigail P. Johnson is also listed as a reporting person with beneficial ownership of the same 65,539,476.75 shares and 5.3% of the class.
The filing states that the securities were acquired and are held in the ordinary course of business and are not intended to change or influence control of Gilead Sciences Inc., other than activities solely in connection with a nomination under Rule 240.14a-11.
Gilead Sciences Chairman & CEO Daniel O'Day reported planned share sales. On 01/28/2026, he sold 5,032 shares of common stock at a weighted average price of $139.5441 and 4,968 shares at $140.2426 in open-market transactions.
These sales were made under a Rule 10b5-1 trading plan adopted on February 28, 2025. After the transactions, O'Day directly owned 556,698 Gilead shares. The first group of sales occurred at prices ranging from $138.99 to $139.97, and the second from $140.00 to $140.57.
Daniel O'Day filed a notice to sell 10,000 common shares through Morgan Stanley Smith Barney LLC on or about 01/28/2026, with an aggregate market value of $1,398,911.00 on NASDAQ.
The 10,000 shares were acquired as performance shares from the issuer on 01/31/2024. Over the past three months, O'Day has already sold 10,000 shares on each of 10/28/2025, 11/28/2025, and 12/29/2025, plus 115,640 shares on 01/23/2026, for gross proceeds ranging from about $1.19 million to $15.61 million per transaction.
Gilead Sciences Chairman and CEO Daniel P. O'Day reported an automatic option exercise and stock sale. On January 23, 2026, he exercised 115,640 non-qualified stock options at an exercise price of $66.01 per share, acquiring the same number of Gilead common shares. On the same day, he sold 115,640 common shares at a price of $135 per share. After these transactions, he directly owned 566,698 shares of Gilead common stock. The filing states that the transaction was carried out under a Rule 10b5-1 trading plan adopted on February 28, 2025, indicating it was pre-arranged under SEC rules.
Daniel O'Day has filed a notice to sell 115,640 shares of common stock, with an aggregate market value of $15,611,400.00, through Morgan Stanley Smith Barney LLC on or about 01/23/2026 on NASDAQ. The filing notes that there were 1,240,679,623 shares of this class outstanding.
The 115,640 shares to be sold were acquired on 01/23/2026 via a stock option exercise from the issuer for cash, in the same amount of 115,640 shares. Over the prior three months, O'Day sold three separate blocks of 10,000 common shares each on 10/28/2025, 11/28/2025, and 12/29/2025, with gross proceeds of $1,193,926.00, $1,265,444.00, and $1,248,272.00, respectively.